Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Achaete-scute family bHLH transcription factor 4 (ASCL4) is a member of the basic helix-loop-helix (bHLH) transcription factor family, essential for the determination of cell fate and the development and differentiation of various tissues. ASCL4, also known as HASH4 and BHLHA44, is characterized by relatively restricted gene expression, particularly prominent in fetal skin compared to adult skin, indicating a unique role in skin development. Current knowledge does not support ASCL4 as a direct therapeutic target, and there is no evidence for clinically relevant drug interactions or established biomarker applications. ASCL4 should not be confused with ACSL4, a gene implicated in lipid metabolism, cancer, and ferroptosis, which is sometimes incorrectly abbreviated as "ASCL4" in the literature. The true ASCL4 described here is best classified as a developmental transcription factor with tissue-specific expression and poorly characterized disease relevance in humans[1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Achaete-scute family bHLH transcription factor 4 (ASCL4).